Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
REVOKED by the SEC: VRAI Viragen, Inc 8/25/2008
SECURITY DELETIONS
Dl Date Symbol Company Name Effective Date/Comments
8/25/2008 VRAI Viragen, Inc. Common Stock 8/26/2008 12(j) Registration Revoked by SEC **
http://www.otcbb.com/asp/dailylist_search.asp?DirectSymbol=VRAI&OTCBB=ALL
A long dead dog here... still somehow "trading".
A potential aspect of past clinical work still could come into play on selling an incremental past portion of a patent consideration.
Doesn't seem likely but I'll hold a write off from years ago... why not?
Whatever, whenever!
Keep in mind VRA still has tech info on hold "and for sale" should the technology get thru the myriad testing now undertaken by others.
Whatever.. whenever.. Riding free.
Looks dead...smells dead.
I'd say this is about it for viragen. bye bye.
This thing has been around forever and never brought in a dime. They are on what seems to be their last legs. About to get booted from AMEX, cancelled the most exciting part of their R&D, still have absolutely no money, etc. They are existing month to month. Halting the OVA development is a good idea, but that was the most interesting thing they were doing IMO. They feel they can focus on the drugs and bring them to market faster than the OVA technology is going to catch on. They pretty much asked for someone to license it in the PR.
I really don't know, I bought it as a lark and decided to hold it. It has potential but playing the odds it will go down at some point.
is this a good stock to buy?
I don't know for sure but based on this company's filings and current situation, I would say they are about done. They can probably sell there OVA technology and get new jobs. My guess is BK coming.
It would be nice if they would have included in the PR what is the basis for their appeal.
News - Will Appeal Delisting Notice!
Up 2.81% at .0329. Chewing the Ask at .0329.
Double Bottom + Huge Bounce Ready. Big Vol.
I bought today on whim. Let's see what happens, shall we?
new here...in 0,087$....it's worth going to bet here! : turn-around or default?...last two PR were encouraging!
Viragen Announces European Multiferon(R) Licensing Agreement
4:02 p.m. 04/18/2007 Provided By PR Newswire Europe
PLANTATION, Florida, Apr 18, 2007 (PR Newswire Europe via COMTEX) -- VRA Receives US$2M Licensing Fee and Multi-Million Dollar Funding Commitment for Melanoma Trial
Viragen, Inc. (VRA) (VRAU) (VRAWS) and its majority-owned subsidiary, Viragen International, Inc. (VGNI), today announced that a licensing agreement has been completed with Swedish Orphan International AB, granting exclusive marketing rights to Multiferon(R) (multi-subtype, human alpha interferon) for the European Union (excluding previously licensed member states).
Under terms of the agreement, Viragen received approximately US$2 million (1.5 million euro) as an up-front license fee and will serve as the sole manufacturer of the product. Swedish Orphan International will pay Viragen for Multiferon(R) at an agreed upon sales price, and, in addition, Viragen will receive double-digit royalties from Swedish Orphan International on their net sales.
Swedish Orphan International will also control and fund a significant portion of the costs for a planned European post-marketing clinical study. The melanoma post-marketing trial will further evaluate the use of Multiferon(R) for the first-line adjuvant treatment of high-risk malignant melanoma (Stages IIb-III).
Multiferon(R), which is manufactured by Viragen International's ViraNative AB subsidiary in Sweden, is currently approved for malignant melanoma and other diseases in Sweden, and the parties will collaborate on registration throughout the European Union with new regulatory approvals expected by early 2008.
Headquartered in Stockholm with a focus on specialty drugs targeting patients with rare, life-threatening diseases, Swedish Orphan International, "The Pioneer Orphan Drug Company", distributes more than 40 drug products throughout Europe in partnerships with more than 30 companies.
President and CEO, Bo Jesper Hansen, welcomed the addition of Multiferon(R) to Swedish Orphan International's product portfolio, "Surgery remains the predominant treatment for malignant melanoma in Europe, however, the risk of relapse remains high for the patients with this severe malignant disease. In Multiferon(R), we are extremely excited about offering a safe, cost-effective, human interferon that can significantly reduce the risk of relapse and extend overall survival, thus giving promise for an increased life expectancy and quality of life for patients with malignant melanoma. Based on our extensive relationships with hospitals, physicians, patient advocacy groups and government agencies, we are committed to making this a priority product in our portfolio, as it holds high potential to emerge as a preferred therapy for patients with malignant melanoma and other severe diseases."
"By licensing Multiferon(R) to one of the fastest growing companies in Europe and with their highly specialized marketing coverage in the orphan indications space, we believe we have the optimal collaborator in place to significantly increase our sales throughout Europe within the next few years," stated Viragen's President and CEO, Charles A. Rice.
Viragen is preparing to proceed with an EU regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.
Mr. Rice added, "For a specialty product such as Multiferon(R), it is of vital importance that we work with an accomplished team for which our drug represents a source of dramatic growth, for them as well as for us. We are confident that Swedish Orphan International will appropriately 'champion' the product, and provide a level of commitment and investment to rapidly advance its uptake throughout Europe."
About Multiferon(R):
Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.
Multiferon(R) differs from single-subtype recombinant alpha interferon drug products in that it contains a unique mixture of multiple subtypes of human interferon (a1, a2, a8, a10, a14, a21). It is believed that each subtype, some of which are glycosylated, employs a specific biological activity, but more importantly, the subtypes act synergistically to elicit an overall effect.
In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is proceeding with a regulatory strategy targeting approvals throughout the broader European Union.
For more on prescription information, please visit: http://www.Multiferon.com
About Swedish Orphan International AB:
Swedish Orphan International, which was established in 1988 in Sweden, has developed into a worldwide pioneer in the field of orphan drugs. Today Swedish Orphan International supplies orphan drugs to around 50 countries, including in Europe as well as the USA, Japan, Australia and Canada. The company's business objective is to develop and make available drugs for the treatment of rare disease patients for which no satisfactory treatment is available. Swedish Orphan International is, since 2004, owned by a consortium comprising Investor Growth Capital ("IGC"), the largest investment company in Scandinavia ( www.investorgrowthcapital.com ), Skandia Investment, a Swedish private equity fund managed by Priveq Investment ( www.priveqinvestment.se ) and Swedish Orphan International's Management.
For more information, please visit: http://www.Swedishorphan.com
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product and product candidate portfolio includes: Multiferon(R) (multi-subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases; VG101, a humanized monoclonal antibody that binds selectively to an antigen over-expressed on Stage IV malignant melanoma tumors; and VG102, a highly novel humanized monoclonal antibody that binds selectively to an antigen that is over-expressed on nearly all solid tumors. We are also pioneering the development of the OVA(TM) System (Avian Transgenics), with the renowned Roslin Institute, the creators of "Dolly the Sheep", as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: +1-954-233-8746; Fax: +1-954-233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third-party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Web site: http://www.viragen.com
http://www.Multiferon.com
http://www.Swedishorphan.com
Douglas Calder, Director of Communications of Viragen, Inc., +1-954-233-8746,
Fax: +1-954-233-1414, dcalder@viragen.com ; Photo:
http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b ; AP Archive:
http://photoarchive.ap.org ; PRN Photo Desk, photodesk@prnewswire.com
Copyright (C) 2007 PR Newswire Europe
Stock is making a NICE move here. Definitely uptrending.
Some poor pathetic loser always trying to make a fast buck off of others.. New alias huh, amazing how people like you come around. Do you live by a freeway?
Any ideas on when we will hear about Multiferon and the Government, and the financing needed for the remaining quarters?
Hopefully Orphan Australia is on its toes getting approval in the Asian/Australian/Pacific region, and we can see some revs coming in by the end of this year. Any thoughts on this? I started eyeballing VRA on the chance this could hopefully be the year VRA gets things going. Any round of financing could be possibly paid off with cash, as to not dilute the o/s.
Thoughts on this?
Gringo42: Alias Born On: Wednesday, March 28, 2007
Which Paid Basher are you?
One issues the stock and the other one dumps it. All the way into sub penny land from $90.00 get out now and save your money. This stock is a scam
I'm out long agi @ 9 cents .... as soon as the buyers left I was gonzo
Enourmeous short again. This is going to sub penny and sub sub penny in my opinion, shorted all the way to extinction. This stock is a dump
Im new to this board but this stock is a dump. Dump meaning too much shorting and private placements. Look at all material changes and stock changes. Management is selling like crazy. I tried to short this stock from April when it was 50 cents I knew it was going down but not like this.
VRA is coming back and it will test the 9 cents again IMO-------held pretty well the 5's so now will test higher ground. I'm up 135% on it
Is this run over???? New to the board; only honest responses.
Thanks!
I know not much chatter, but that's okay. I'm in at low .03's with 500K shares AVG.. holding all still.
This is a GOLDEN EGG
even with volume over the past few days, it has traded primarily "under the radar".
It should be around a dime, if not higher. With news, we can see it run much higher. This is an AMEX stock, not a pinky or BB stock.
tomorrow will be enormous
VRA - nice gapper fro Friday
jimmy, I agree...
I also bought at .025 and have no intention on selling for now... Stay tuned for the rest of the story....
I bought at .025 so I will be selling half soon or all if it looses steam here.
How long are you staying in???
Press Release Source: Viragen, Inc.
Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal
Tuesday January 16, 9:06 am ET
PLANTATION, Fla., Jan. 16 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA; VRA.U; VRA.WS) and its collaborative partners in the field of avian transgenics, Roslin Institute and Oxford Biomedica Plc (LSE: OXB - News), today announced that the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a leading scientific journal, has published an article profiling the OVA(TM) System's ability to express two therapeutic proteins in the whites of eggs of transgenic hens. The OVA(TM) System is being developed as a novel, large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins.
The article, entitled, "Oviduct-specific expression of two therapeutic proteins in transgenic hens," reports on the production of two protein drug candidates: a humanized monoclonal antibody being developed by Viragen for advanced malignant melanoma; and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of Multiple Sclerosis (MS), as Avonex®* (Biogen Idec) and Rebif®** (Serono).
Looks like they have till March to meet compliance requirements Of AMEX.
All the best
Spoke to company today -
There are certainly risks here (as with all stocks under $1.oo)
However:
- - They are alive and well (the doors are open)
- - They have product (high potential product)
- - They are working on licensing and distribution
- - Their manufacturing facility is up and running
- - They are working to maintain AMEX listing
- - MULTIFERON is for real and approved for sale internationally
http://www.viragen.com/multiferon.htm
Jim
A classic scam, still holding a pps. Bizarre enough to hold for some damned reason other than common sense.
Had to post for the hell of it! We got an education and our monetary ass handed to us here.
At least this POS and associated management are write offs for the future. I, for one, intend to flag every frigging corporate name involved and rightly bash them until my fingers bleed on this keyboard.
Yes, I invested "on hope" but.... now it's evolved beyond education to a LONG TERM vengance attitude.
Viragen International, Inc. is a subsidiary of Viragen, Inc
What's the connection between VRA and VGNI?
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
76
|
Created
|
05/18/03
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |